| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 44.33B | 41.95B | 40.11B | 43.65B | 43.08B | 34.61B |
| Cost of revenue | 19.32B | 18.71B | 17.98B | 19.14B | 18.54B | 15.00B |
| Gross profit | 25.01B | 23.24B | 22.13B | 24.51B | 24.54B | 19.61B |
| Research and development | 2.94B | 2.84B | 2.74B | 2.89B | 2.74B | 2.42B |
| Selling, general and admin | 12.33B | 11.70B | 10.95B | 11.25B | 11.32B | 9.70B |
| Operating expenses | 36.27B | 35.13B | 33.63B | 35.29B | 34.65B | 29.25B |
| Operating income | 8.05B | 6.83B | 6.48B | 8.36B | 8.43B | 5.36B |
| EBITDA | 9.49B | 8.16B | 7.75B | 9.62B | 9.92B | 6.55B |
| Interest expense | 493.00M | 559.00M | 637.00M | 558.00M | 533.00M | 546.00M |
| Income before tax | 8.47B | 7.01B | 6.66B | 8.31B | 8.21B | 4.97B |
| Income tax | 1.94B | -6.39B | 941.00M | 1.37B | 1.14B | 497.00M |
| Net income | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B | 4.50B |
| EPS | 3.73 | 7.67 | 3.28 | 3.94 | 3.97 | 2.52 |
| EPS (diluted) | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 |
| Diluted shares | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B |
| Dividends per share | 2.40 | 2.24 | 2.08 | 1.92 |
From Abbott Laboratories's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.